Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

被引：0
|
作者：
Relinde I. Y. Lieverse
Evert J. Van Limbergen
Cary J. G. Oberije
Esther G. C. Troost
Sine R. Hadrup
Anne-Marie C. Dingemans
Lizza E. L. Hendriks
Franziska Eckert
Crispin Hiley
Christophe Dooms
Yolande Lievens
Monique C. de Jong
Johan Bussink
Xavier Geets
Vincenzo Valentini
Giuliano Elia
Dario Neri
Charlotte Billiet
Amir Abdollahi
David Pasquier
Pierre Boisselier
Ala Yaromina
Dirk De Ruysscher
Ludwig J. Dubois
Philippe Lambin
机构：
[1] Maastricht University,The D
[2] Maastricht University Medical Center,Lab and The M
[3] Faculty of Medicine and University Hospital Carl Gustav Carus at Technische Universität Dresden,Lab, Department of Precision Medicine, GROW
[4] OncoRay, School for Oncology and Developmental Biology
[5] National Center for Radiation Research in Oncology,Department of Radiation Oncology (MAASTRO), GROW
[6] Technical University of Denmark, School for Oncology and Developmental Biology
[7] Erasmus MC Rotterdam,Department of Radiotherapy and Radiation Oncology
[8] Maastricht University Medical Centre,Department of Health Technology
[9] University Hospital and Medical Faculty Tübingen,Department of Pulmonary Medicine
[10] Eberhard Karls University Tübingen,Department of Pulmonary Diseases, GROW
[11] University College London Cancer Institute, School for Oncology and Developmental Biology
[12] University Hospitals KU Leuven,Department of Radiation Oncology
[13] Ghent University Hospital and Ghent University,Cancer Research UK Lung Cancer Centre of Excellence
[14] Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital,Department of Respiratory Diseases, Respiratory Oncology Unit
[15] Radboud University Medical Center,Department of Radiation Oncology
[16] Cliniques Universitaires Saint-Luc,Department of Radiation Oncology
[17] MIRO - IREC Lab,Department of Radiation Oncology
[18] UCL,Department of Radiation Oncology
[19] Fondazione Policlinico Universitario A. Gemelli IRCCS,Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia
[20] Università Cattolica del Sacro Cuore,Department of Chemistry and Applied Biosciences
[21] Istituto di Radiologia,Department of Radiation Oncology
[22] Philochem AG,University of Antwerp
[23] Institute of Pharmaceutical Sciences,Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology
[24] ETH Zurich,Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT)
[25] Iridium Network,Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO)
[26] Faculty of Medicine and Health Sciences,Academic Department of Radiation Oncology
[27] Campus Drie Eiken,Department of Radiation Oncology, ICM
[28] Building S,Val d’Aurelle
[29] Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD),undefined
[30] Heidelberg Ion-Beam Therapy Center (HIT),undefined
[31] Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ),undefined
[32] German Cancer Consortium (DKTK) Core Center,undefined
[33] Heidelberg University and German Cancer Research Center (DKFZ),undefined
[34] Oscar Lambret Comprehensive Cancer Center,undefined
[35] Université de Montpellier,undefined
来源：
BMC Cancer | / 20卷
关键词：
Immunotherapy; L19-IL2; Anti-PD-L1; Anti-PD-1; Radiotherapy; SABR; Phase 2; NSCLC; Stage IV; Multicentre;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
    Lieverse, Relinde I. Y.
    Van Limbergen, Evert J.
    Oberije, Cary J. G.
    Troost, Esther G. C.
    Hadrup, Sine R.
    Dingemans, Anne-Marie C.
    Hendriks, Lizza E. L.
    Eckert, Franziska
    Hiley, Crispin
    Dooms, Christophe
    Lievens, Yolande
    de Jong, Monique C.
    Bussink, Johan
    Geets, Xavier
    Valentini, Vincenzo
    Elia, Giuliano
    Neri, Dario
    Billiet, Charlotte
    Abdollahi, Amir
    Pasquier, David
    Boisselier, Pierre
    Yaromina, Ala
    De Ruysscher, Dirk
    Dubois, Ludwig J.
    Lambin, Philippe
    BMC CANCER, 2020, 20 (01)
  • [2] Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
    Palma, David A.
    Olson, Robert
    Harrow, Stephen
    Gaede, Stewart
    Louie, Alexander V.
    Haasbeek, Cornelis
    Mulroy, Liam
    Lock, Michael
    Rodrigues, George B.
    Yaremko, Brian P.
    Schellenberg, Devin
    Ahmad, Belal
    Griffioen, Gwendolyn
    Senthi, Sashendra
    Swaminath, Anand
    Kopek, Neil
    Liu, Mitchell
    Moore, Karen
    Currie, Suzanne
    Bauman, Glenn S.
    Warner, Andrew
    Senan, Suresh
    LANCET, 2019, 393 (10185): : 2051 - 2058
  • [3] Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
    Sahgal, Arjun
    Myrehaug, Sten D.
    Siva, Shankar
    Masucci, Giuseppina L.
    Maralani, Pejman J.
    Brundage, Michael
    Butler, James
    Chow, Edward
    Fehlings, Michael G.
    Foote, Mathew
    Gabos, Zsolt
    Greenspoon, Jeffrey
    Kerba, Marc
    Lee, Young
    Liu, Mitchell
    Liu, Stanley K.
    Thibault, Isabelle
    Wong, Rebecca K.
    Hum, Maaike
    Ding, Keyue
    Parulekar, Wendy R.
    LANCET ONCOLOGY, 2021, 22 (07): : 1023 - 1033
  • [4] Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
    Ball, David
    Mai, G. Tao
    Vinod, Shalini
    Babington, Scott
    Ruben, Jeremy
    Kron, Tomas
    Chesson, Brent
    Herschtal, Alan
    Vanevski, Marijana
    Rezo, Angela
    Elder, Christine
    Skala, Marketa
    Wirth, Andrew
    Wheeler, Greg
    Lim, Adeline
    Shaw, Mark
    Schofield, Penelope
    Irving, Louis
    Solomon, Benjamin
    LANCET ONCOLOGY, 2019, 20 (04): : 494 - 503
  • [5] Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care
    Shah, Pallav L.
    Orton, Christopher M.
    Grinsztejn, Beatriz
    Donaldson, Gavin C.
    Ramirez, Brenda Crabtree
    Tonkin, James
    Santos, Breno R.
    Cardoso, Sandra W.
    Ritchie, Andrew, I
    Conway, Francesca
    Riberio, Maria P. D.
    Wiseman, Dexter J.
    Tana, Anand
    Vijayakumar, Bavithra
    Caneja, Cielito
    Leaper, Craig
    Mann, Bobby
    Samson, Anda
    Bhavsar, Pankaj K.
    Boffito, Marta
    Johnson, Mark R.
    Pozniak, Anton
    Pelly, Michael
    LANCET RESPIRATORY MEDICINE, 2023, 11 (05): : 415 - 424
  • [6] The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT)
    Abdel-Aty, H.
    Amos, C. L.
    Brown, L. C.
    Yogeswaran, Y.
    Niem, P.
    Dutey-Magni, P.
    Kasivisvanathan, V.
    Bennett, R.
    Clarke, N.
    Sachdeva, A.
    Cross, W.
    Farrelly, L.
    Matheson, D.
    Peedell, C.
    Diez, P.
    Naismith, O.
    Parmar, M. K.
    Attard, G.
    van As, N.
    James, N. D.
    ANNALS OF ONCOLOGY, 2024, 35 : S999 - S999
  • [7] Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
    Zhu, Xiaofei
    Cao, Yangsen
    Liu, Wenyu
    Ju, Xiaoping
    Zhao, Xianzhi
    Jiang, Lingong
    Ye, Yusheng
    Jin, Gang
    Zhang, Huojun
    LANCET ONCOLOGY, 2022, 23 (03): : E105 - E115
  • [8] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
    Ader, Florence
    Bouscambert-Duchamp, Maude
    Hites, Maya
    Peiffer-Smadja, Nathan
    Poissy, Julien
    Belhadi, Drifa
    Diallo, Alpha
    Le, Minh-Patrick
    Peytavin, Gilles
    Staub, Therese
    Greil, Richard
    Guedj, Jeremie
    Paiva, Jose-Artur
    Costagliola, Dominique
    Yazdanpanah, Yazdan
    Burdet, Charles
    Mentre, France
    LANCET INFECTIOUS DISEASES, 2022, 22 (02): : 209 - 221
  • [9] RETRACTED: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial (Retracted Article)
    Zhu, Xiaofei
    Cao, Yangsen
    Liu, Wenyu
    Ju, Xiaoping
    Zhao, Xianzhi
    Jiang, Lingong
    Ye, Yusheng
    Jin, Gang
    Zhang, Huojun
    LANCET ONCOLOGY, 2021, 22 (08): : 1093 - 1102
  • [10] Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial
    Balata, Mahmoud
    Radbruch, Lukas
    Hesse, Michaela
    Westenfeld, Ralf
    Neukirchen, Martin
    Pfister, Roman
    Batzler, Yann-Nicolas
    Oeztuerk, Can
    Kavsur, Refik
    Tiyerili, Vedat
    Weltermann, Birgitta
    Poelsler, Robert
    Standl, Thomas
    Nickenig, Georg
    Becher, Marc Ulrich
    LANCET HEALTHY LONGEVITY, 2024, 5 (10):
12345